DN-1289 is a potent and selective dual DLK/LZK inhibitor. DN1289 demonstrated excellent in vivo plasma half-life across species and is anticipated to freely penetrate the central nervous system with no brain impairment based on in vivo rodent pharmacokinetic studies and human in vitro transporter data. Proximal target engagement and disease relevant pathway biomarkers were also favorably regulated in an in vivo model of amyotrophic lateral sclerosis.
MedKoo Cat#: 122408
Name: DN-1289
CAS#: N/A
Chemical Formula: C18H19F4N7O2
Exact Mass: 441.1536
Molecular Weight: 441.39
Elemental Analysis: C, 48.98; H, 4.34; F, 17.22; N, 22.21; O, 7.25
The following data is based on the product molecular weight 441.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
